Skip to main content

Jaguar Health, Inc. (JAGX)

NASDAQ: JAGX · Delayed Price · USD
-0.06 (-4.35%)
At close: Nov 29, 2021 4:00 PM
-0.01 (-0.76%)
Pre-market:Nov 30, 2021 7:22 AM EST

Company Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea.

It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas.

It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera.

The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.

Jaguar Health, Inc.
Jaguar Health Logo
CountryUnited States
SectorHealth Care
CEOLisa Conte

Contact Details

200 Pine Street Suite 400
San Francisco, California 94104
United States
Phone415 371 8300

Stock Details

Ticker SymbolJAGX
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001585608

Key Executives

Lisa A. ConteFounder, Chief Executive Officer, President and Director
Jonathan S. Wolin CPA, J.D., M.B.A.Chief of Staff, Chief Compliance Officer and General Counsel
Dr. Steven R. KingChief Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary
Carol R. LizakChief Financial Officer
Dr. Pravin R. Chaturvedi Ph.D.Chair of Scientific Advisory Board and Acting Chief Scientific Officer
Peter HodgeSenior Director of Investor Relations, Business Development and Special Events
Dr. Karen Brunke Ph.D.Executive Vice President of Corporate and Business Development
David SesinChief Manufacturing Officer
Ian H. Wendt M.B.A.Chief Commercial Officer
Melissa A. Yeager J.D.Senior Vice President of Regulatory Affairs and Quality Assurance

Latest SEC Filings

Nov 23, 20218-KCurrent report
Nov 22, 2021S-3Registration statement under Securities Act of 1933
Nov 18, 20218-KCurrent report
Nov 17, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 15, 2021NT 10-QNotification of inability to timely file Form 10-Q or 10-QSB
Sep 23, 2021DNotice of Exempt Offering of Securities
Sep 17, 20218-KCurrent report
Sep 3, 20218-KCurrent report
Aug 24, 20218-KCurrent report
Aug 24, 2021DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
View All SEC Filings